精準醫療領域的合作與授權協議（2019-2026 年）

Precision Medicine Collaboration and Licensing Deals 2019-2026

出版日期: 2026年05月01日 | 出版商:

Current Partnering | 英文 700+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

精準醫療領域交易的權威基準

精準醫療領域的合作是由數據、診斷和標靶治療的整合所驅動的，其合約結構反映了患者分層策略和日益個性化的治療方法。

本報告對超過 1350 項精準醫療合作及許可協議進行了全面系統的分析，清晰且基於證據地闡述了整個市場夥伴關係的設計、談判和執行方式。

清楚了解市場標準

本報告對精準醫療領域的合約實際構成方式進行了精確闡述。

類似交易的可靠基準
對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
定義切合實際的市場參數
清楚洞察基於技術類型、治療領域和合作夥伴概況的合約條款差異。
支持基於證據的評估和合約結構確定。
讓內部討論基於實際交易數據，而不是僅基於假設。
了解主要公司的交易方式
以數據主導，高度整合地視覺化整個治療領域的合作夥伴行為模式和迭代合約結構。
完全透明地了解合約的結構和執行情況
本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

授予和保留的權利
負責開發和商業化
財務結構和付款條款
關鍵合約條款和保護措施
這種透明度對於理解精準醫療領域合作中價值、風險和控制權的分配至關重要。在需要診斷、治療和數據平台之間協作的領域，其重要性更為突出。
專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

建置和基準測試精準醫療交易
在清晰的市場環境下準備談判
跨部門夥伴關係及交易對象評估
利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

超過 1350 項與精準醫療相關的合作與許可協議。
財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
可全文搜尋的合約目錄（按公司、技術和治療領域）
可直接查閱向美國證券交易委員會提交的合約和原始文件。
合約趨勢、重大交易和活躍合約方分析。
精準醫療領域交易的可靠依證參考資料。
本報告結合了全面的合約資料涵蓋和詳細的合約層面分析，為在精準醫療領域建立、談判和評估夥伴關係提供了可靠的、依證的資源。

過去幾年在精準醫療領域的合作
精準醫療產業中最活躍的參與者
精準醫療服務合約：依合約類型分類
精準醫療服務合約：依治療區域分類
精準醫療合約：依行業分類
精準醫療服務合約條款
- 標題金額
- 預付款
- 里程碑付款
- 權利金費率

第3章主要精準醫療合約

按合約金額排名的精準醫療服務合約

第4章：精準醫療最活躍領域的締約方

精準醫療領域最活躍的合約方
精準醫療領域最活躍簽約方的公司簡介

第5章：精準醫療合約目錄

第6章精準醫療合約：依技術類型分類

合約目錄
合約目錄：依公司名稱（A-Z）排列的精準醫療合約
合約目錄：依合約類型分類的精準醫療合約
合約目錄：按治療領域分類的精準醫療合約
合約類型的定義
關於 Biopharma Research Ltd.
關於當前合作夥伴關係
關於現行協議
Current Partnering 最新報告列表

簡介目錄

Product Code: CP2108

The definitive benchmark for precision medicine dealmaking

Precision medicine partnering is driven by the integration of data, diagnostics, and targeted therapies, with deal structures reflecting patient stratification strategies and increasingly personalised approaches to treatment.

This report provides a comprehensive and structured analysis of 1350+ precision medicine collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how precision medicine deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by technology type, therapeutic alignment, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a data-driven and highly integrated therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within precision medicine partnerships, particularly where coordination across diagnostics, therapeutics, and data platforms is required.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark precision medicine transactions
Prepare for negotiations with well-defined market context
Evaluate cross-functional partnerships and counterparties
Support internal strategy with robust, defensible data
What's included
1350+ precision medicine collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, technology, and therapeutic alignment)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for precision medicine dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how precision medicine partnerships are structured, negotiated, and valued.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine dealmaking

2.1. Introduction
2.2. Precision medicine deals over the years
2.3. Most active precision medicine dealmakers
2.4. Precision medicine deals by deal type
2.5. Precision medicine deals by therapy area
2.6. Precision medicine deals by industry sector
2.7. Deal terms for precision medicine deals
- 2.7.1 Precision medicine deals headline values
- 2.7.2 Precision medicine deal upfront payments
- 2.7.3 Precision medicine deal milestone payments
- 2.7.4 Precision medicine royalty rates